Skill Tracer
Skills › Scientific Agent Skills › peer-review › statistical_reproducibility.md

statistical_reproducibility.md

329 lines · skills/peer-review/references/statistical_reproducibility.md at 5f2bc03

Open on GitHub

Most marks come from matching words in the file, so treat them as pointers.

1# Statistical, Methods, and Reproducibility Review
2
3This guide supports structured questions; it does not replace a statistician, methodologist, domain expert, or independent reanalysis. Sources reviewed on **2026-10-01**, with source-specific verification limits, are recorded in `assets/source_ledger.csv`.
4

Statistical, Methods, and Reproducibility Review

This guide supports structured questions; it does not replace a statistician, methodologist, domain expert, or independent reanalysis. Sources reviewed on 2026-10-01, with source-specific verification limits, are recorded in assets/source_ledger.csv.

Raw lines 1 to 4
5## Evidence hierarchy for the review
6
7Use, in order:
8
91. The stated research question and target population
102. Protocol, registration, analysis plan, and amendments
113. Reported design and data-generating process
124. Methods, code, tables, figures, supplements, and repository records
135. Applicable primary method or regulatory guidance
146. Current reporting guidance
157. Target venue policy
17Do not reject a method merely because another method is more familiar. Explain the estimand, assumption, error, or interpretation at stake.

Evidence hierarchy for the review

Use, in order:

  1. The stated research question and target population
  2. Protocol, registration, analysis plan, and amendments
  3. Reported design and data-generating process
  4. Methods, code, tables, figures, supplements, and repository records
  5. Applicable primary method or regulatory guidance
  6. Current reporting guidance
  7. Target venue policy

Do not reject a method merely because another method is more familiar. Explain the estimand, assumption, error, or interpretation at stake.

Raw lines 5 to 18
19## Core review sequence

Core review sequence

Raw lines 19 to 20
21### 1. Define what is being estimated
23Write down:
25- Unit of inference
26- Population
27- Intervention, exposure, test, or predictors
28- Comparator or reference condition
29- Outcome and time horizon
30- Target effect, association, accuracy, or predictive performance
31- Intercurrent events, censoring, and missing observations where relevant
33Then trace whether design, data collection, analysis, result, and claim target the same quantity.
35For applicable clinical trials, ICH E9(R1) provides a framework for estimands and sensitivity analyses. It is not a universal rule for every study.

1. Define what is being estimated

Write down:

  • Unit of inference
  • Population
  • Intervention, exposure, test, or predictors
  • Comparator or reference condition
  • Outcome and time horizon
  • Target effect, association, accuracy, or predictive performance
  • Intercurrent events, censoring, and missing observations where relevant

Then trace whether design, data collection, analysis, result, and claim target the same quantity.

For applicable clinical trials, ICH E9(R1) provides a framework for estimands and sensitivity analyses. It is not a universal rule for every study.

Raw lines 21 to 36
37### 2. Reconstruct the design
39Identify:
41- Prospective, retrospective, cross-sectional, longitudinal, experimental, or observational structure
42- Recruitment or sampling frame
43- Experimental/observational unit
44- Pairing, nesting, clustering, repeated measures, sites, batches, and time
45- Allocation, concealment, blinding, matching, or weighting
46- Primary and secondary outcomes
47- Prespecified versus exploratory analyses
49If the design cannot be reconstructed, first request missing reporting. Do not label the design invalid solely because details are absent.

2. Reconstruct the design

Identify:

  • Prospective, retrospective, cross-sectional, longitudinal, experimental, or observational structure
  • Recruitment or sampling frame
  • Experimental/observational unit
  • Pairing, nesting, clustering, repeated measures, sites, batches, and time
  • Allocation, concealment, blinding, matching, or weighting
  • Primary and secondary outcomes
  • Prespecified versus exploratory analyses

If the design cannot be reconstructed, first request missing reporting. Do not label the design invalid solely because details are absent.

Raw lines 37 to 50
51### 3. Trace every denominator
53Reconcile:
55- Eligible, enrolled, assigned, treated/exposed, followed, measured, and analyzed units
56- Outcome-specific denominators
57- Exclusions before and after allocation or measurement
58- Missing values and reasons
59- Complete-case, imputed, weighted, or model-based analysis populations
60- Figure, table, abstract, text, and supplement totals
62Report the exact mismatch and locations; do not infer why counts differ.

3. Trace every denominator

Reconcile:

  • Eligible, enrolled, assigned, treated/exposed, followed, measured, and analyzed units
  • Outcome-specific denominators
  • Exclusions before and after allocation or measurement
  • Missing values and reasons
  • Complete-case, imputed, weighted, or model-based analysis populations
  • Figure, table, abstract, text, and supplement totals

Report the exact mismatch and locations; do not infer why counts differ.

Raw lines 51 to 63
64### 4. Assess analysis–design alignment
66Ask whether the method accounts for:
68- Outcome scale and distribution
69- Pairing and repeated measures
70- Clustering and multilevel structure
71- Unequal follow-up, censoring, or competing events
72- Sampling weights or matched designs
73- Baseline adjustment and prespecified covariates
74- Multiplicity and outcome hierarchy
75- Model tuning and validation
76- Missingness assumptions
78The name of a statistical test is not enough. The report should state inputs, model form, uncertainty method, software/version, and relevant diagnostics.

4. Assess analysis–design alignment

Ask whether the method accounts for:

  • Outcome scale and distribution
  • Pairing and repeated measures
  • Clustering and multilevel structure
  • Unequal follow-up, censoring, or competing events
  • Sampling weights or matched designs
  • Baseline adjustment and prespecified covariates
  • Multiplicity and outcome hierarchy
  • Model tuning and validation
  • Missingness assumptions

The name of a statistical test is not enough. The report should state inputs, model form, uncertainty method, software/version, and relevant diagnostics.

Raw lines 64 to 79
80### 5. Assess estimates and interpretation
82Prefer:
84- Effect or performance estimates with units
85- Compatible uncertainty intervals
86- Absolute as well as relative quantities when decision-relevant
87- Exact denominators and analysis sets
88- Assumption and sensitivity context
89- Clinical, biological, policy, or practical relevance distinct from statistical compatibility
91The ASA’s six p-value principles include:
93- A p-value is about incompatibility with a specified model, not the probability a hypothesis is true.
94- Threshold crossing alone should not determine scientific conclusions.
95- Transparent reporting of all relevant analyses is required.
96- Statistical significance does not measure effect size or importance.
97- A p-value alone is not a good measure of evidence.
99SAMPL provides concise biomedical statistical reporting guidance. Apply it as reporting guidance, not a universal analysis recipe.

5. Assess estimates and interpretation

Prefer:

  • Effect or performance estimates with units
  • Compatible uncertainty intervals
  • Absolute as well as relative quantities when decision-relevant
  • Exact denominators and analysis sets
  • Assumption and sensitivity context
  • Clinical, biological, policy, or practical relevance distinct from statistical compatibility

The ASA’s six p-value principles include:

  • A p-value is about incompatibility with a specified model, not the probability a hypothesis is true.
  • Threshold crossing alone should not determine scientific conclusions.
  • Transparent reporting of all relevant analyses is required.
  • Statistical significance does not measure effect size or importance.
  • A p-value alone is not a good measure of evidence.

SAMPL provides concise biomedical statistical reporting guidance. Apply it as reporting guidance, not a universal analysis recipe.

Raw lines 80 to 100
101## Topic-specific checks

Topic-specific checks

Raw lines 101 to 102
103### Sample size and precision
105Look for:
107- Prospective calculation or precision rationale
108- Target effect or interval width
109- Variance, event rate, prevalence, or accuracy assumptions
110- Type I error, power, sidedness, and multiplicity when applicable
111- Design effect, clustering, attrition, noncompliance, and missingness
112- Model complexity and effective sample size
113- Simulation details for complex designs
115Do not request observed/post hoc power as a remedy for an imprecise result. Examine the estimate and uncertainty.

Sample size and precision

Look for:

  • Prospective calculation or precision rationale
  • Target effect or interval width
  • Variance, event rate, prevalence, or accuracy assumptions
  • Type I error, power, sidedness, and multiplicity when applicable
  • Design effect, clustering, attrition, noncompliance, and missingness
  • Model complexity and effective sample size
  • Simulation details for complex designs

Do not request observed/post hoc power as a remedy for an imprecise result. Examine the estimate and uncertainty.

Raw lines 103 to 116
117### Randomized trials
119Check:
121- Allocation sequence and concealment
122- Prespecified estimand and analysis population
123- Protocol/registry/outcome consistency
124- Baseline adjustment and stratification factors
125- Intercurrent events, adherence, treatment switching, and missing data
126- Harms and unintended effects
127- Sensitivity and supplementary analyses
128- Non-inferiority/equivalence margin and interpretation if relevant
130Use CONSORT 2025 and SPIRIT 2025 for reporting. Use ICH E9/E9(R1) only when its scope and decision context fit.

Randomized trials

Check:

  • Allocation sequence and concealment
  • Prespecified estimand and analysis population
  • Protocol/registry/outcome consistency
  • Baseline adjustment and stratification factors
  • Intercurrent events, adherence, treatment switching, and missing data
  • Harms and unintended effects
  • Sensitivity and supplementary analyses
  • Non-inferiority/equivalence margin and interpretation if relevant

Use CONSORT 2025 and SPIRIT 2025 for reporting. Use ICH E9/E9(R1) only when its scope and decision context fit.

Raw lines 117 to 131
132### Observational causal analyses
134Check:
136- Causal question and target contrast
137- Time zero, eligibility, treatment/exposure assignment, follow-up, and outcome timing
138- Confounder rationale and measurement timing
139- Positivity/overlap
140- Exchangeability and consistency assumptions
141- Missingness, censoring, selection, and measurement error
142- Model specification and balance diagnostics
143- Sensitivity to unmeasured confounding or alternative specifications
145Avoid judging causal identification from adjusted versus unadjusted p-values.

Observational causal analyses

Check:

  • Causal question and target contrast
  • Time zero, eligibility, treatment/exposure assignment, follow-up, and outcome timing
  • Confounder rationale and measurement timing
  • Positivity/overlap
  • Exchangeability and consistency assumptions
  • Missingness, censoring, selection, and measurement error
  • Model specification and balance diagnostics
  • Sensitivity to unmeasured confounding or alternative specifications

Avoid judging causal identification from adjusted versus unadjusted p-values.

Raw lines 132 to 146
147### Diagnostic accuracy
149Check:
151- Intended use, setting, and participant spectrum
152- Index test and reference standard
153- Threshold prespecification
154- Blinding and timing
155- Indeterminate/missing results
156- Verification and incorporation bias
157- Two-by-two denominators and uncertainty
158- External applicability
160STARD/STARD-AI describe reporting; use an appropriate risk-of-bias framework separately.

Diagnostic accuracy

Check:

  • Intended use, setting, and participant spectrum
  • Index test and reference standard
  • Threshold prespecification
  • Blinding and timing
  • Indeterminate/missing results
  • Verification and incorporation bias
  • Two-by-two denominators and uncertainty
  • External applicability

STARD/STARD-AI describe reporting; use an appropriate risk-of-bias framework separately.

Raw lines 147 to 161
162### Prediction models
164Check:
166- Intended use, prediction time, outcome, and target population
167- Data source and participant flow
168- Predictor availability at intended use
169- Missing-data and preprocessing leakage
170- Sample size relative to outcome information and complexity
171- Internal validation and optimism correction
172- Independent evaluation and dataset shift
173- Calibration, discrimination, decision utility, and uncertainty
174- Hyperparameter tuning separated from evaluation
175- Reproducible model specification and preprocessing
176- Subgroup performance tied to plausible use and harms
178TRIPOD+AI replaces TRIPOD 2015 for regression and machine-learning prediction model reporting. STARD-AI is more appropriate when diagnostic accuracy of an index test is the primary aim.

Prediction models

Check:

  • Intended use, prediction time, outcome, and target population
  • Data source and participant flow
  • Predictor availability at intended use
  • Missing-data and preprocessing leakage
  • Sample size relative to outcome information and complexity
  • Internal validation and optimism correction
  • Independent evaluation and dataset shift
  • Calibration, discrimination, decision utility, and uncertainty
  • Hyperparameter tuning separated from evaluation
  • Reproducible model specification and preprocessing
  • Subgroup performance tied to plausible use and harms

TRIPOD+AI replaces TRIPOD 2015 for regression and machine-learning prediction model reporting. STARD-AI is more appropriate when diagnostic accuracy of an index test is the primary aim.

Raw lines 162 to 179
180### Systematic reviews and meta-analyses
182Check:
184- Protocol and registration
185- Eligibility criteria and information sources
186- Reproducible search dates and strategies
187- Duplicate screening/extraction processes or justified alternatives
188- Risk-of-bias assessment
189- Effect measure and synthesis model
190- Heterogeneity and prediction intervals when appropriate
191- Dependence among estimates
192- Small-study and reporting biases
193- Certainty assessment, if claimed
194- Transparent deviations and unavailable data
196PRISMA 2020 assesses reporting. Do not substitute PRISMA coverage for review-conduct appraisal.

Systematic reviews and meta-analyses

Check:

  • Protocol and registration
  • Eligibility criteria and information sources
  • Reproducible search dates and strategies
  • Duplicate screening/extraction processes or justified alternatives
  • Risk-of-bias assessment
  • Effect measure and synthesis model
  • Heterogeneity and prediction intervals when appropriate
  • Dependence among estimates
  • Small-study and reporting biases
  • Certainty assessment, if claimed
  • Transparent deviations and unavailable data

PRISMA 2020 assesses reporting. Do not substitute PRISMA coverage for review-conduct appraisal.

Raw lines 180 to 197
198### Clustered and longitudinal data
200Check:
202- Level of assignment, measurement, and inference
203- Within-cluster/subject correlation
204- Number and distribution of clusters
205- Small-cluster corrections where needed
206- Time structure, nonlinear change, and irregular measurement
207- Informative visit, dropout, or censoring processes
208- Cluster-level versus individual-level covariates
210Repeated observations do not increase independent sample size one-for-one.

Clustered and longitudinal data

Check:

  • Level of assignment, measurement, and inference
  • Within-cluster/subject correlation
  • Number and distribution of clusters
  • Small-cluster corrections where needed
  • Time structure, nonlinear change, and irregular measurement
  • Informative visit, dropout, or censoring processes
  • Cluster-level versus individual-level covariates

Repeated observations do not increase independent sample size one-for-one.

Raw lines 198 to 211
212### Multiplicity
214Identify the inferential family before recommending adjustment:
216- Multiple primary outcomes
217- Multiple intervention arms or contrasts
218- Repeated time points
219- Subgroups and interactions
220- Interim analyses
221- High-dimensional features
222- Model selection
224Possible responses include hierarchical testing, family-wise control, false-discovery control, multilevel modeling, transparent exploratory labeling, or emphasis on estimates and uncertainty. The remedy depends on the claim and decision rule.

Multiplicity

Identify the inferential family before recommending adjustment:

  • Multiple primary outcomes
  • Multiple intervention arms or contrasts
  • Repeated time points
  • Subgroups and interactions
  • Interim analyses
  • High-dimensional features
  • Model selection

Possible responses include hierarchical testing, family-wise control, false-discovery control, multilevel modeling, transparent exploratory labeling, or emphasis on estimates and uncertainty. The remedy depends on the claim and decision rule.

Raw lines 212 to 225
226### Missing data
228Check:
230- Missingness by group, variable, outcome, and time
231- Reasons and relation to intercurrent events
232- Information used by imputation or weighting
233- Number of imputations and pooling when applicable
234- Compatibility of imputation and analysis models
235- Uncertainty propagation
236- Sensitivity to plausible departures from assumptions
238Avoid demanding one preferred technique without considering the estimand and missingness process.

Missing data

Check:

  • Missingness by group, variable, outcome, and time
  • Reasons and relation to intercurrent events
  • Information used by imputation or weighting
  • Number of imputations and pooling when applicable
  • Compatibility of imputation and analysis models
  • Uncertainty propagation
  • Sensitivity to plausible departures from assumptions

Avoid demanding one preferred technique without considering the estimand and missingness process.

Raw lines 226 to 239
240## Reproducibility review

Reproducibility review

Raw lines 240 to 241
242### Materials and provenance
244Check:
246- Stable identifiers for datasets, samples, models, protocols, and materials
247- Raw-to-processed provenance
248- Exclusion and transformation records
249- Versioned analysis inputs and outputs
250- Repository accession numbers
251- Data dictionary, units, and coding
252- Domain metadata standard where applicable
254Legacy domain standards and their current status are summarized in `references/reporting_standards.md`.

Materials and provenance

Check:

  • Stable identifiers for datasets, samples, models, protocols, and materials
  • Raw-to-processed provenance
  • Exclusion and transformation records
  • Versioned analysis inputs and outputs
  • Repository accession numbers
  • Data dictionary, units, and coding
  • Domain metadata standard where applicable

Legacy domain standards and their current status are summarized in references/reporting_standards.md.

Raw lines 242 to 255
256### Code and computational environment
258Check:
260- Executable code for central analyses when sharing is permitted
261- Dependency versions or lock/environment file
262- Operating-system or hardware requirements that affect results
263- Random seeds and nondeterminism
264- Parameter, configuration, and model checkpoints
265- Run order and instructions
266- Tests or validation of custom code
267- License and access restrictions
269Code availability does not prove that the code generated the reported result. Provenance and a reproducible run record are separate evidence.

Code and computational environment

Check:

  • Executable code for central analyses when sharing is permitted
  • Dependency versions or lock/environment file
  • Operating-system or hardware requirements that affect results
  • Random seeds and nondeterminism
  • Parameter, configuration, and model checkpoints
  • Run order and instructions
  • Tests or validation of custom code
  • License and access restrictions

Code availability does not prove that the code generated the reported result. Provenance and a reproducible run record are separate evidence.

Raw lines 256 to 270
271### Data and access
273Open sharing may be limited by consent, privacy, indigenous/community governance, security, contracts, or licensing. A useful statement should identify:
275- What exists
276- Where it is held
277- Who can request access
278- Criteria and process
279- Expected timeline
280- Restrictions and rationale
281- Whether code or synthetic/aggregate alternatives are available
283Do not request disclosure that would violate ethics, law, consent, or governance.

Data and access

Open sharing may be limited by consent, privacy, indigenous/community governance, security, contracts, or licensing. A useful statement should identify:

  • What exists
  • Where it is held
  • Who can request access
  • Criteria and process
  • Expected timeline
  • Restrictions and rationale
  • Whether code or synthetic/aggregate alternatives are available

Do not request disclosure that would violate ethics, law, consent, or governance.

Raw lines 271 to 284
285### Independent reproduction
287Claim independent reproduction only if the reviewer actually:
2891. Obtained authorized inputs.
2902. Recorded versions and environment.
2913. Ran documented commands.
2924. Preserved content hashes or equivalent provenance.
2935. Compared prespecified outputs.
2946. Recorded deviations and failures.
296A static consistency audit is not reproduction.

Independent reproduction

Claim independent reproduction only if the reviewer actually:

  1. Obtained authorized inputs.
  2. Recorded versions and environment.
  3. Ran documented commands.
  4. Preserved content hashes or equivalent provenance.
  5. Compared prespecified outputs.
  6. Recorded deviations and failures.

A static consistency audit is not reproduction.

Raw lines 285 to 297
298## When to request specialist review
300Escalate when a central conclusion depends on methods outside competence, including:
302- Complex adaptive, Bayesian, causal, survival, multilevel, spatial, or longitudinal methods
303- High-dimensional omics or multiple-testing procedures
304- Diagnostic, prediction, or AI evaluation
305- Survey weighting or complex sampling
306- Economic modeling
307- Meta-analysis with dependent effects or network structure
308- Unfamiliar qualitative or mixed-methods methodology
309- Image forensics, biosecurity, privacy, or domain-specific ethics
311Say what expertise is needed and which claim depends on it. Do not mask uncertainty with an automated score.

When to request specialist review

Escalate when a central conclusion depends on methods outside competence, including:

  • Complex adaptive, Bayesian, causal, survival, multilevel, spatial, or longitudinal methods
  • High-dimensional omics or multiple-testing procedures
  • Diagnostic, prediction, or AI evaluation
  • Survey weighting or complex sampling
  • Economic modeling
  • Meta-analysis with dependent effects or network structure
  • Unfamiliar qualitative or mixed-methods methodology
  • Image forensics, biosecurity, privacy, or domain-specific ethics

Say what expertise is needed and which claim depends on it. Do not mask uncertainty with an automated score.

Raw lines 298 to 312
313## Using the local checklist
315Copy `assets/statistical_reproducibility_template.json`, record evidence locations without pasting manuscript prose into report fields, and run:
317```bash
318python3 scripts/audit_statistics_reproducibility.py local-checklist.json
319```
321Statuses:
323- `verified_present`
324- `partly_documented`
325- `missing`
326- `not_assessed`
327- `not_applicable` with rationale
329The tool reports item IDs and counts. It does not calculate merit, rerun analyses, or certify reproducibility.

Using the local checklist

Copy assets/statistical_reproducibility_template.json, record evidence locations without pasting manuscript prose into report fields, and run:

python3 scripts/audit_statistics_reproducibility.py local-checklist.json

Statuses:

  • verified_present
  • partly_documented
  • missing
  • not_assessed
  • not_applicable with rationale

The tool reports item IDs and counts. It does not calculate merit, rerun analyses, or certify reproducibility.

Raw lines 313 to 329
Runs code python3 scripts/audit_statistics_reproducibility.py :318